- Open Access
The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor
Journal of Neuroinflammation volume 9, Article number: 211 (2012)
Post-ischemic microglial activation may contribute to neuronal damage through the release of large amounts of pro-inflammatory cytokines and neurotoxic factors. The involvement of microRNAs (miRNAs) in the pathogenesis of disorders related to the brain and central nervous system has been previously studied, but it remains unknown whether the production of pro-inflammatory cytokines is regulated by miRNAs.
BV-2 and primary rat microglial cells were activated by exposure to oxygen-glucose deprivation (OGD). Global cerebral ischemia was induced using the four-vessel occlusion (4-VO) model in rats. Induction of pro-inflammatory and neurotoxic factors, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and nitric oxide (NO), were assessed by ELISA, immunofluorescence, and the Griess assay, respectively. The miRNA expression profiles of OGD-activated BV-2 cells were subsequently compared with the profiles of resting cells in a miRNA microarray. BV-2 and primary rat microglial cells were transfected with miR-181c to evaluate its effects on TNF-α production after OGD. In addition, a luciferase reporter assay was conducted to confirm whether TNF-α is a direct target of miR-181c.
OGD induced BV-2 microglial activation in vitro, as indicated by the overproduction of TNF-α, IL-1β, and NO. Global cerebral ischemia/reperfusion injury induced microglial activation and the release of pro-inflammatory cytokines in the hippocampus. OGD also downregulated miR-181c expression and upregulated TNF-α expression. Overproduction of TNF-α after OGD-induced microglial activation provoked neuronal apoptosis, whereas the ectopic expression of miR-181c partially protected neurons from cell death caused by OGD-activated microglia. RNAinterference-mediated knockdown of TNF-α phenocopied the effect of miR-181c-mediated neuronal protection, whereas overexpression of TNF-α blocked the miR-181c-dependent suppression of apoptosis. Further studies showed that miR-181c could directly target the 3′-untranslated region of TNF-α mRNA, suppressing its mRNA and protein expression.
Our data suggest a potential role for miR-181c in the regulation of TNF-α expression after ischemia/hypoxia and microglia-mediated neuronal injury.
Microglia are the resident innate immune cells of the CNS. Microglia display a quiescent phenotype in the healthy brain, but they become highly activated after brain insult, when they produce reactive oxygen and nitrogen species and pro-inflammatory cytokines [1–5]. Therefore, microglial cells play important roles in the surveillance of and response to pathological insults . The available evidence has indicated that microglial activation results in the overproduction of pro-inflammatory cytokines, which may contribute to the development and progression of neurodegenerative disorders . For example, activated microglia and their secreted factors, such as tumor necrosis factor (TNF)-α, are key mediators of neuroinflammation, which have been shown to correlate with neurodegenerative diseases such as Alzheimer’s disease [8, 9], Parkinson’s disease [10, 11] and HIV-associated dementia [12, 13]. In addition, activated microglia, by releasing pro-inflammatory cytokines, participate in the inflammatory response associated with cerebral ischemia . Overproduction of inflammatory factors from ischemia-activated microglia is thought to mediate post-ischemic neuronal damage .
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules, 22to 25 nucleotides in length, that function in the post-transcriptional regulation of gene expression. miRNAs bind partly complementary sequences in mRNAs, targeting them for degradation and/or inhibiting their translation, and thereby downregulating the expression of the targeted proteins . Dysregulation of miRNAs has been shown to contribute to many types of human diseases, including neuronaldisorders [16–18]. However, there are almost no data on the miRNA expression profiles of microglial cells exposed to hypoxia. Although microglial activation is considered to be the hallmark of neuroinflammation , it remains unknown whether expression of pro-inflammatory cytokines during microglial activation is regulated by miRNAs.
In this study, we used oxygen-glucose deprivation (OGD)-activated microglial cells, which are characterized by the overproduction of pro-inflammatory and neurotoxic factors. Wefound that OGD downregulated miR-181c expression but upregulated TNF-α expression. The overproduction of TNF-α that followed OGD-induced microglial activation induced neuronal apoptosis, whereas ectopic expression of miR-181c partially protected neurons from cell death caused by OGD-activated microglia. Therefore, our data suggest an important role for miR-181c in the regulation of TNF-α expression after ischemia/hypoxia and microglia-mediated neuronal injury.
All cell culture products were purchased from Gibco (Carlsbad, CA, USA). The following antibodies were used: anti-CD11b (Millipore, Bedford, MA, USA), anti-TNF-α, anti-inducible nitric oxide synthase (iNOS; Abcam, Cambridge, MA, USA), anti-interleukin (IL)-1β (Santa Cruz Biotechnology, CA, USA), and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology, Beverly, MA, USA). Recombinant soluble (s)TNF was purchased from Peprotech (Rocky Hill, NJ, USA).
Microglial cell culture
The Shanghai Medical Experimental Animal Care Committee approved the protocol for this study, and all animal experiments were conducted in accordance with the National Institutes of HealthGuidelines for the Care and Use of Laboratory Animals.
Primary hippocampal microglial cells were isolated from glial cultures prepared from newborn (less than 24 hours old) Sprague–Dawley (SD) rats(Laboratory Animal Center, Shanghai Medical College, Fudan University, Shanghai, China). Glial cells were cultured in 75 cm2 flasks for 14 days in DMEM/F12 (Gibco BRL, Grand Island, NY, USA) supplemented with 10% FCS(Hyclone, Logan, UT, USA), 100 U/ml penicillin and 100 mg/ml streptomycin. Microglia were isolated from primary mixed glial cell cultures on day 10 by shaking the flasks overnight at 300 rpm on a rotary shaker at 37°C. The purity of the microglial cultures was assessed as over 90%, using a CD11b antibody. Cells were cultured for 2 daysbefore treatment.
The BV-2 murine microglial cell line and rat primarycultured microglial cells were maintained in DMEM supplemented with 10% FCS.
Oxygen-glucose deprivation and preparation of microglial conditioned medium
OGD was performed with the microglial cells as reported previously , with minor modifications. Briefly, microglial cells were initially maintainedin serum/glucose-free DMEM in an anoxic (95% N2 and 5% CO2) environment at 37°C for 1 hour. The cells were then transferred to a normoxic incubator (95% air, 5% CO2) and maintained in serum-free defined medium.At 48 hours after OGD, the medium conditioned with the microglial cells was harvested. This fresh, conditioned medium was cleared by centrifugation and diluted 1:1 with serum-free defined medium, then used to treat the neurons For all experiments, conditioned media from the indicated microglia were collected simultaneously and used in parallel.
Transient forebrain ischemia was induced by four-vessel occlusion (4-VO) as described by Pulsinelli . Briefly, male Wistar rats weighing 260 to 320 g were anesthetized with 4% (w/v) chloral hydrate 400 mg/kg administered intraperitoneally. The bilateral vertebral arteries were permanently electrocauterized and the bilateral common carotid arteries (CCAs) were freed,then atraumatic clasps were placed around the CCAs without interrupting the arterial blood flow. The rats were allowed to recover for 24 hours after the surgical incisions were closed. On the next day, the rats were anesthetized, and forebrain ischemia was induced by tightening the clasps for 20 minutes. The clasps were then removed for reperfusion. In sham-operated groups, the same procedure was performed without the 4-VO procedure.
At 3 daysafter ischemia induction, animals were deeply anesthetized, then killed by perfusion with saline, followed by 4% paraformaldehyde in 0.1 mol/L phosphate buffer (pH 7.4). Brains were removed and post-fixed for 4 hours in the same fixative, then embedded in optimum cutting temperature compound, and stored at −70°C. Serial sections (20 μm in thickness) were cut on a cryostat. Only those regions that contained the same coronal plane as the hippocampus were evaluated.
Sections were incubated with primary antibodies against anti-CD11b (mouse monoclonal antibody; dilution 1:300) and anti-iNOS (rabbit monoclonal; dilution 1:100) overnight at 4°C. After thorough washing, the cells were incubated with fluorescein isothiocyanate-conjugated anti-rabbit IgG (goat, 1:500 dilution; Santa Cruz Biotechnology) or with DyLight 649-conjugated anti-mouse IgG (goat, 1:500 dilution; Santa Cruz Biotechnology) for 1.5 hours at room temperature. Finally, the cells were washed and mounted with mounting medium containing DAPI (Vector Laboratories). A negative control, in which the primary antibody was omitted, was used to test for the specificity of the antibody being used. The images were captured using a conventional fluorescence microscope (Leica, Heerbrugg, Switzerland).
Primary culturing of hippocampal neurons
Primary hippocampal neuronal cultures were prepared as described previously . Briefly, the hippocampi of newborn (< 24 hours old) SD rats were dissected and incubated in Hank’s balanced salt solution without Ca2+ or Mg2+. The tissues were subsequently dissociated using 0.125% trypsin (Gibco BRL, Grand Island, NY, USA) by digesting for 15 minutes at 37°C followed by gentle trituration through a flame-polished Pasteur pipette. The dissociated cells were seeded onto glass coverslips coated with poly-L-lysine (molecular weight 30,000 to 70,000, 0.1 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) or into 24-well plates at a density of 1 × 106 cells/ml. The cells were cultured in serum-free medium (Neurobasal-A; Gibco BRL,Gaithersburg, MD, USA) and supplemented with 2% B27 (Gibco BRL), 10 μL/ml penicillin-streptomycin and 2 mmol/l glutamine (Solarbio). The cells were maintained by changing the medium every 2–3 days and incubating at 37.8°C in a humidified atmosphere containing 5% CO2. The purity of the neuronal cultures was determined by immunocytochemical staining using an antibody against neurofilament proteins (a neuron-specific marker). and more than 90% of the cells were found to be neurons.
Hoechst staining assay for apoptosis
For Hoechst 33342 staining, neurons were fixed in 4% paraformaldehyde and incubated for 10 minutes at room temperature with 5 μg/ml Hoechst 33342 (Sigma Chemical Co, St. Louis, MO). Cells were analyzed using a conventional fluorescence microscope (Leica), and the neurons with clearly condensed and segmented chromatin were counted as apoptotic. For all of the groups, 300 cells (including the normal and apoptotic cells) were counted manner using fluorescence microscopy by a researcher blinded to the treatment given. Three independent experiments were performed for each group.
RNA isolation, microarrays, and real-timePCR
Total RNA was extracted from the BV-2 or primary cultured cells (both with and without OGD treatment) using TRIzol reagent (Invitrogen, San Diego, CA, USA) in accordance with the manufacturer’s instructions. Small RNAs were isolated using a commercial kit (miRNA Isolation Kit; Ambion, Inc., Austin, TX, USA). Array experiments were performed by a company (CapitalBio Corp., Beijing, China) as described on the company’s website ( http://www.capitalbio.com) and in previous reports [21, 22], using an miRNA array (GeneChip miRNA Array; Affymetrix Inc., Santa Clara, CA, USA),which is composed of 6,703 probe sets from the miRNAs registered in the Sanger miRBase miRNA database (version 11; http://microrna.sanger.ac.uk; accessed 15 April 15 2008). Semi-quantitative real-time PCR, using SYBR Green I, was conducted to compare the relative expression levels of specific mRNAs, as described previously . TaqMan miRNA assays (Applied Biosystems Inc., Carlsbad, CA, USA) were used to quantify mature miRNA expression levels,in accordance with the manufacturer’s protocol. For each of the selected miRNAs, real-time PCR measurements were performed to obtain a mean CT value for each sample. The CT valuesof the different samples were compared using the 2-ΔΔCT method , and U6 expression levels were used as an internal reference.
Western blotting analysis
Western blotting was performed as described previously . Briefly, total protein was extracted from cultured cells and quantified using a commercial bicinchoninic acid (BCA) kit(BCA Protein Assay Kit; Pierce Biotechnology Inc., Rockford, IL, USA) with BSA as the standard. Equal amounts of protein from different cells were separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5% non-fat milk, and incubated with primary antibodies against TNF-α (rabbit polyclonal; 1:500 dilution) and GAPDH (rabbit monoclonal; 1:3000 dilution). The blots were then incubated for 2 hours at room temperature with horseradish peroxidase-conjugated secondary antibodies (goat; 1:3000 dilution) in blocking buffer and appropriate secondary antibodies. Target proteins were detected using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Uppsala, Sweden).
Measurement of cytokine release by enzyme-linked immunosorbent assay
To detect the levels of pro-inflammatory factors in the hippocampus, rats were killed at defined time points. Brain homogenates were obtained from the hippocampi ,and separated by centrifugation at 14,000 g for 5 minutes at 4°C to remove cellular debris. The supernatant was stored at −80°C until use. To detect cytokine secretion in microglial supernatants in response to OGD, cells were plated intosix-well plates and exposed to OGD or normoxic conditions, as described above. After 48 hours, the media were collected and stored at −80°C until use. The concentrations of IL-1β and TNF-α in the stored media were measured using a sandwich ELISA kit (DuoSet; R&D Systems, Minneapolis, MN, USA).
Nitric oxide production assay
Nitric oxide (NO) levels were determined by measuring the levels of the stable metabolite nitrite in the culture medium, as described previously . Briefly, BV-2 or primary rat microglial cells in 24-well plates (2 × 105 cells in 500 ml/well) were exposed to OGD. Sample aliquots (100 ml) were mixed with 100 ml Griess reagent and incubated at 25°C for 10 minutes. Absorbance at 550 nm was measured on a microplate reader.
The miRNA duplexes corresponding to miR-181c were designed as described previously . The control RNA duplexes (referred to as NC for ‘negative control’) for the miRNA mimics and the small interfering RNAs (siRNAs) were not homologous to any human gene sequences. The siRNAs were synthesized by targeting mouse TNF-α (GenBank accessnumber NM_013693) transcripts. The sequences of the RNA oligoribonucleotides (Genepharma, Shanghai, China)are shown in Table 1. Oligonucleotide transfection was performed with commercialreagents (Lipofectamine 2000; Invitrogen Corp.). Each transfection used 50 nmol/L of RNA duplexes.
Vector construction and luciferase reporter assays
To generate the miR-181c expression vector, the miR-181c gene was amplified from mouse genomic DNA and cloned into the pcDNA3.0 vector (Invitrogen Corp.). The open reading frame of the mouse TNF-α gene was amplified and cloned into the pcDNA3.0 vector. The luciferase complexes were constructed by ligating oligonucleotides containing the wild-type or mutated putative target site of the mouse TNF-α 3′-untranslated region (UTR) into the multi-cloning site of the p-MIR luciferase reporter vector (Ambion Inc., Austin, TX, USA). HEK293 or BV-2 cells were cotransfected with 80 ng of the luciferase reporter plasmid, 40 ng of the pRL-TK-Renilla-luciferase plasmid (Promega Corp., Madison, WI, USA), and the indicated RNAs (final concentration 20 nmol/l). At 24 hours after the transfection, the firefly and Renilla luciferase activities were measured (Dual-Luciferase Reporter Assay; Promega Corp.). Each transfection was repeated twice in triplicate.
All data are expressed as the mean ± SE of at least three independent experiments performed in triplicate. Statistical analyses were performed using ANOVA models and Student’s t-tests. P < 0.05 were considered significant.
Hypoxia/ischemia induces microglial activation and the release of pro-inflammatory cytokines and neurotoxic factors
Microglia activated by ischemic conditions have been shown to release pro-inflammatory and neurotoxic factors, such as IL-1, TNF-α and NO, which may be responsible for severe brain-tissue damage [2, 3]. Therefore, real-time PCR and ELISA were used to assess the induction of IL-1β and TNF-α in BV-2 microglia exposed to OGD. BV-2 cells were activated after OGD (Figure 1), characterized by the overexpression of IL-1β and TNF-α mRNA as detected by real-time PCR, and by the secretion of the cytokines IL-1β and TNF-α as detected by ELISA. In addition, OGD caused expression of iNOSand mRNA, and overproduction of the neurotoxic factor, NO (Figure 1C,F).
We further confirmed these effects in a rat model. We induced 20 minutes of global cerebral ischemia by 4-VO in rats, and studied the microglial activation and release of pro-inflammatory cytokines in the hippocampus. We evaluated microglial activation 3 days afterI/R. We detected increased levels of IL-1β and TNF-α in the hippocampus by ELISA (Figure 1G). After 3 days of I/R, the number of microglia was markedly increased in the hippocampal CA1 region. By contrast, only a few scattered ramified microglia (resting microglia) were seen in sham-operated rats (Figure 1H). In addition, immunofluorescence showed that transient global cerebral I/R significantly increased expression of iNOS in the hippocampus (Figure 1H). These results indicate that hypoxia/ischemia induces microglial activation and the release of pro-inflammatory cytokines and neurotoxic factors.
Oxygen-glucose deprivation upregulates tumor necrosis factor-α expression and downregulates microRNA (miR)-181c expression in BV-2 cells
We further evaluated the miRNA expression profiles of the OGD-activated BV-2 cells compared with the resting cells by miRNA microarray. The thresholdfoldchange value to screen for upregulated and downregulated miRNAs was ≥1.5. In total, 26 miRNAs that exhibited significantly altered expression levels between the hypoxic and normoxic conditions were identified. Of these 26 miRNAs, 7 were upregulated and 19 were downregulated. miR-181c exhibited the highest degree of downregulation in the activated microglia (Figure 2A). Subsequent database searches of both the TargetScan ( http://www.targetscan.org) and Sanger ( http://microrna.sanger.ac.uk) sitesshowed that TNF-α mRNAs have conserved miR-181c recognition sites in their 3′-UTRs (Figure 2B). It is generally accepted that miRNAs exert their function by downregulating the expression of their downstream target genes. To confirm this inverse correlation between the expression of miR-181c and TNF-α found in this study, we measured the mRNA expression levels of TNF-α at different time points after OGD treatment. TNF-α exhibited increased levels of mRNA expression, whereas expression of miR-181c was significantly decreased after treatment (Figure 2C). These results confirmed an inverse correlation between expression of miR-181c and TNF-α during hypoxia-induced microglial activation.
Tumor necrosis factor-α is a direct target of microRNA (miR)-181c
As detailed above, OGD upregulated TNF-α and downregulated miR-181c expression in microglial cells. We hypothesized that increased TNF-α production might result from the downregulation of miR-181c. To address this hypothesis, a dual-luciferase reporter system was used (Figure 3A). Coexpression of miR-181c significantly suppressed the firefly luciferase reporter activity of the wild-type 3′-UTR but not of the mutant 3′-UTR in both HEK193T (Figure 3B) and BV-2 cells (Figure 3C), indicating that miR-181c suppresses TNF-α expression through miRNA binding sequences in its 3′-UTR. Finally, BV-2 cells were transfected with the NC or miR-181c duplexes. miR-181c was capable of significantly suppressing the mRNA and protein expression of TNF-α (Figure 3D). Taken together, this result suggests that miR-181c suppresses TNF-α expression by binding to the 3′-UTR, and that TNF-α is a direct target of miR-181c.
Ectopic expression of microRNA (miR)-181c attenuates oxygen-glucose deprivation-activated BV2-induced neuronal apoptosis
TNF-α is a key pro-inflammatory cytokine, and increased levels of this cytokine have been associated with the pathology of a variety of neurological, neurodegenerative, and neurotoxic conditions . TNF-α can activate receptor-mediated pro-apoptotic pathways within the neuron. TNF-α can also stimulate microglial activation in the form of iNOS induction, which leads to the production of NO, a neurotoxic factor associated with brain injury . Therefore, we transfected microglial cells with NC or miR-181c mimics and treated the microglial cells with OGD. Evaluation of the harvested microglia-conditioned mediumshowed that the miR-181c-transfected cells secreted less TNF-α after OGD (Figure 4A). In addition, the miR-181c-transfected cells exhibited decreased iNOS expression and NO production (Figure 4B). To confirm whether the ectopic miR-181c expression was able to attenuate activated microglia-induced neuronal death, neurons were exposed to cell-free conditioned medium collected from microglia with or without the ectopic expression of miR-181c. The ectopic expression of miR-181c significantly reduced the neuronal apoptosis induced by OGD-activated microglia (Figure 4C,D), suggesting that ectopic expression of miR-181c attenuates OGD-activated BV2-induced neuronal apoptosis.
microRNA (miR)-181c controls microglia-mediated neuronal apoptosis and is dependent on tumor necrosis factor-α
To clarify the role of microglia-derived TNF-α in miR-181c-mediated neuronal apoptosis, we first tested the capacity of TNF-α to trigger death in cultured neurons. We found that addition of soluble (s)TNF-α to the neuron culture triggered apoptosis in a dose-dependent manner (Figure 5A). Furthermore, addition of sTNF-α significantly abrogated miR-181c-mediated neuronal survival (Figure 5B). Next, the effects of TNF-α silencing on neuronal apoptosis were determined. We found that silencing of TNF-α in the microglia-conditioned media significantly decreased both TNF-α production (Figure 5C) and microglia-mediated neuronal apoptosis (Figure 5D), which was similar to the phenotype induced by miR-181c. By contrast, the ectopic expression of TNF-α using a TNF-α expression vector that encoded the entire coding sequence of TNF but lacked its 3′-UTR expression significantly abrogated miR-181c-induced neuronal survival (Figure 5E,F), indicating that TNF-α is a functional target for miR-181c.
microRNA (miR)-181c controls tumor necrosis factor-α production in primary rat microglial cells
To confirm the observations from the primary rat microglia, primary-culturenewborn rat microglial cells were used. As seenwith the BV-2 cells, miR-181c transfection significantly suppressed basal TNF-α mRNA and protein expression levels (Figure 6A,B). In addition, OGD led to overproduction of secreted TNF-α in the primary rat microglia, whereas ectopic expression of miR-181c significantly reduced TNF-α production (Figure 6C). This system was also used to confirm that ectopic expression of miR-181c-attenuated neuronal death was caused by activated primary rat microglia (Figure 6D). Finally, as seen with the BV-2 cells, we found that miR-181c inhibited OGD-induced iNOS expression and NO production in primary rat microglia (Figure 6E,F). Taken together, the results indicate that miR-181c controls microglia-mediated neuronal apoptosis by suppressing TNF-α production (Figure 7).
To our knowledge, this study is the first to report the miRNA expression profile of microglial cells exposed to ischemia, although it is already becoming clear that miRNA-dependent post-transcriptional gene regulation plays pivotal roles at all stages of neural development . In addition, for the first time, we have also identified in microglia a microRNA, miR-181c, whichcan directly regulate TNF-α production post-transcription.
Inflammation is an underlying component of a diverse range of neurodegenerative diseases and their associated neuropathologies. Increasing evidence suggests that microglia are a key causative factor in this process [7, 31]. Activated microglia serve initially to phagocytose necrotic debris, which allows for the eventual healing of the injured brain. However, under pathological conditions, activated microglia can induce significant and strongly detrimental neurotoxic effects through excess production of a large array of cytotoxic factors, such as IL-1β, NO, reactive oxygen species (ROS), and TNF-α [1, 32]. In our study, we found that OGD upregulated IL-1β, TNF-α, and iNOS. However, although microglial activation is considered to be a hallmark of neuroinflammation, whether the expression of pro-inflammatory cytokines is regulated by miRNAs during microglial activation has not been previously determined. Therefore, after identifying the miRNA profile of ischemia-activated microglia, we investigated the correlation between altered miRNA expression and pro-inflammatory cytokines.
TNF-α is a key pro-inflammatory cytokine that has been reported to play an important role in the events that follow ischemia . Increased levels of TNF-α have been associated with the pathological effects of a variety of infectious, neurological, neurodegenerative, and neurotoxic conditions . We analyzed the predicted TNF-α-regulating miRNAs that were downregulated in activated microglial cells, and found that TNF-α might be regulated by miR-181c. To better understand this regulatory relationship, the capacity of miR-181c to directly regulate TNF-α expression by binding to its 3′-UTR was confirmed. To determine whether the dysregulated miRNAs were functional, we confirmed that ectopic expression of miR-181c resulted in decreased release of TNF-α from the microglial cells and decreased neuronal apoptosis. Silencing TNF-α also produced a significant decrease in neuronal apoptosis in microglia-conditioned media, which was similar to the phenotype induced by miR-181c. Additionally, ectopic TNF-α expression significantly abrogated the neuronal survivalinducec by miR-181c. All these results suggest that miRNAs represent endogenous functional microglial moleculesthat respond to ischemia and produce a neurotoxic phenotype in microglia. Taken together, the results from our study suggest that some miRNAs lie upstream of pro-inflammatory cytokines or other inflammatory mediators. However, we cannot exclude the possibility that some of the miRNAs that were upregulated in the activated microglia play a role because they may act upstream of several anti-inflammatory genes.
An increasing body of evidence indicates that oxidative stress resulting from excessive generation of ROS and reactive nitrogen species (RNS) is a causal factor in various neurodegenerative disorders . The interaction between NO and superoxide anion-forming toxic peroxynitritehas been proposed as being involved in neuronal injury [35, 36]. TNF-α can activate receptor-mediated proapoptotic pathways within the neuron, and can further stimulate the microglia through iNOS and cyclooxygenase 2 induction [28, 29]. Therefore, inhibition of TNF-α production is expected to be beneficial in inflammation-related neurological disorders. In our study, we found that OGD resulted in increased production of NO, whereas ectopic expression of miR-181c could suppress expression of iNOS, leading to decreased production of NO. Therefore, our study indicates an important role of miR-181c in TNF-α-mediated neurotoxicity after ischemia (Figure 7).
Our study also demonstrates the importance of investigating the mechanisms underlying cytokine regulation when studying the effect of cytokines on neuronal injury, because this information may facilitate the development of more effective therapeutic interventions. Previous studies have shown enhancement of neuronal damage by TNF-α in vivo in ischemia models. For example, intracerebroventricular administration of TNF-α increased the lesional area produced by focal ischemia, whereas inhibition of TNF-α activity by administration of soluble TNF-α receptors or anti-TNF-α antibodies reduced the ischemic damage . Clinical studies on the effects produced by modification of cytokines in CNS disease are currently underway. At present, the main challenge is to deliver sufficient levels of cytokines or their modifiers to the ischemic or injured brain. miRNAs may represent a new drug target class. By taking advantage of their small size and the current knowledge of miRNA biogenesis, modified RNAs can be transiently delivered as synthetic, pre-processed miRNAs or as anti-miRNA oligonucleotides .
Delivering an miRNA that reduces the protein levels of target genes linked to a particular disease by post-transcriptional regulation or that targets a particular functional miRNA linked to a particular disease represents new therapeutic options. A recent study has shown that the in vivo administration of miR-124 suppresses experimental autoimmune encephalitisby affecting macrophages, suggesting that miRNA delivery could be used to treat some inflammatory diseases associated with microglial activation . A recent report also showed that another member of the miR-181c family, miR-181a, could influence cerebral ischemia outcomes in vitro and in vivo by regulating GRP78 expression in astrocytes . Collectively, all of these studies have indicated that manipulating miRNA levels could be a potential treatment strategy for ischemic brain injury.
We identified a correlation between miRNA levels and the expression of genes involved in pro-inflammatory cytokine production. We also characterized one particular molecular series, the miR-181c-TNF-α pathway, which is partially responsible for microglia-mediated neuronal apoptosis. Our data suggest a potential role for miR-181c in the regulation of TNF-α expression after ischemia/hypoxia and microglia-mediated neuronal injury.
bovine serum albumin
central nervous system
enzyme-linked immunosorbent assay
fetal calf serum
inducible nitric oxide synthase
reactive nitrogen species
reactive oxygen species
small interfering RNA
tumor necrosis factor.
Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, Feuerstein GZ: Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994, 25:1481–1488.
Hoehn BD, Palmer TD, Steinberg GK: Neurogenesis in rats after focal cerebral ischemia is enhanced by indomethacin. Stroke 2005, 36:2718–2724.
Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999, 96:13496–13500.
Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O: Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003, 100:13632–13637.
Griffin WS, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GW: Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett 1994, 176:133–136.
Graeber MB, Streit WJ: Microglia: biology and pathology. Acta Neuropathol 2010, 119:89–105.
Mrak RE, Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26:349–354.
Eikelenboom P, Rozemuller AJ, Hoozemans JJ, Veerhuis R, van Gool WA: Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis Assoc Disord 2000,14(Suppl 1):S54-S61.
Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M: Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 2007, 28:533–536.
Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW: Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100:34–41.
Matusevicius D, Navikas V, Soderstrom M, Xiao BG, Haglund M, Fredrikson S, Link H: Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol 1996, 66:115–123.
Achim CL, Heyes MP, Wiley CA: Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 1993, 91:2769–2775.
Wesselingh SL, Takahashi K, Glass JD, McArthur JC, Griffin JW, Griffin DE: Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. J Neuroimmunol 1997, 74:1–8.
Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357–365.
Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009, 10:126–139.
Rajasethupathy P, Fiumara F, Sheridan R, Betel D, Puthanveettil SV, Russo JJ, Sander C, Tuschl T, Kandel E: Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron 2009, 63:803–817.
Konopka W, Kiryk A, Novak M, Herwerth M, Parkitna JR, Wawrzyniak M, Kowarsch A, Michaluk P, Dzwonek J, Arnsperger T, Wilczynski G, Merkenschlager M, Theis FJ, Kohr G, Kaczmarek L, Schutz G: MicroRNA loss enhances learning and memory in mice. J Neurosci 2010, 30:14835–14842.
Liu N, Landreh M, Cao K, Abe M, Hendriks GJ, Kennerdell JR, Zhu Y, Wang LS, Bonini NM: The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila. Nature 2012, 482:519–523.
Badiola N, Malagelada C, Llecha N, Hidalgo J, Comella JX, Sabria J, Rodriguez-Alvarez J: Activation of caspase-8 by tumour necrosis factor receptor 1 is necessary for caspase-3 activation and apoptosis in oxygen-glucose deprived cultured cortical cells. Neurobiol Dis 2009, 35:438–447.
Liu B, Zhang H, Xu C, Yang G, Tao J, Huang J, Wu J, Duan X, Cao Y, Dong J: Neuroprotective effects of icariin on corticosterone-induced apoptosis in primary cultured rat hippocampal neurons. Brain Res 2011, 1375:59–67.
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009, 69:1135–1142.
Zhang Y, Cui Y, Zhou Z, Sha J, Li Y, Liu J: Altered global gene expressions of human placentae subjected to assisted reproductive technology treatments. Placenta 2010, 31:251–258.
Lekanne Deprez RH, Fijnvandraat AC, Ruijter JM, Moorman AF: Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal Biochem 2002, 307:63–69.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 2001, 25:402–408.
Nicolas FJ, Hill CS: Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 2003, 22:3698–3711.
Lee YJ, Choi DY, Choi IS, Han JY, Jeong HS, Han SB, Oh KW, Hong JT: Inhibitory effect of a tyrosine-fructose Maillard reaction product, 2,4-bis(p-hydroxyphenyl)-2-butenal on amyloid-beta generation and inflammatory reactions via inhibition of NF-kappaB and STAT3 activation in cultured astrocytes and microglial BV-2 cells. J Neuroinflammation 2011, 8:132.
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769–773.
Park KM, Bowers WJ: Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010, 22:977–983.
Hermes G, Ajioka JW, Kelly KA, Mui E, Roberts F, Kasza K, Mayr T, Kirisits MJ, Wollmann R, Ferguson DJ, Roberts CW, Hwang JH, Trendler T, Kennan RP, Suzuki Y, Reardon C, Hickey WF, Chen L, McLeod R: Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation 2008, 5:48.
Schratt G: Fine-tuning neural gene expression with microRNAs. Curr Opin Neurobiol 2009, 19:213–219.
Brown GC, Neher JJ: Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010, 41:242–247.
Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57–69.
McCoy MK, Tansey MG: TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45.
Wang JY, Wen LL, Huang YN, Chen YT, Ku MC: Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr Pharm Des 2006, 12:3521–3533.
Beckman JS, Chen J, Crow JP, Ye YZ: Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 1994, 103:371–380.
Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS: A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993, 364:626–632.
Hosomi N, Ban CR, Naya T, Takahashi T, Guo P, Song XY, Kohno M: Tumor necrosis factor-alpha neutralization reduced cerebral edema through inhibition of matrix metalloproteinase production after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2005, 25:959–967.
Medina PP, Slack FJ: Inhibiting microRNA function in vivo. Nat Methods 2009, 6:37–38.
Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL: MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2011, 17:64–70.
Ouyang YB, Lu Y, Yue S, Xu LJ, Xiong XX, White RE, Sun X, Giffard RG: miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo. Neurobiol Dis 2012, 45:555–563.
We thank Jian-Min Luo for superior technical assistance. This study was supported by funds from National Science Fundation of China (81100795), Shanghai Key Program for Basic Research, Shanghai, China (10JC1404700) and Research Project of Health Bureau of Shanghai Municipality, Shanghai, China (2009Y018).
The authors declare no competing financial interests.
LZ and WSW designed the research; LZ, LYD, YJL, ZH, and WSW performed the research; LZ, LYD, YJL, and WSW analyzed data; and LZ and WSW wrote the paper. All authors read and approved the final manuscript.
About this article
Cite this article
Zhang, L., Dong, LY., Li, YJ. et al. The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor. J Neuroinflammation 9, 211 (2012). https://doi.org/10.1186/1742-2094-9-211
- Microglial activation
- Neuronal apoptosis